BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rodrigo E, Segundo DS, Fernández-Fresnedo G, López-Hoyos M, Benito A, Ruiz JC, de Cos MA, Arias M. Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development. Transplantation 2016;100:2479-85. [PMID: 26703349 DOI: 10.1097/TP.0000000000001040] [Cited by in Crossref: 113] [Cited by in F6Publishing: 46] [Article Influence: 22.6] [Reference Citation Analysis]
Number Citing Articles
1 Shen CL, Yang AH, Lien TJ, Tarng DC, Yang CY. Tacrolimus Blood Level Fluctuation Predisposes to Coexisting BK Virus Nephropathy and Acute Allograft Rejection. Sci Rep 2017;7:1986. [PMID: 28512328 DOI: 10.1038/s41598-017-02140-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
2 Song T, Yin S, Jiang Y, Huang Z, Liu J, Wang Z, Li L, Zeng J, Fan Y, Wang X, Li X, Lin T. Increasing Time in Therapeutic Range of Tacrolimus in the First Year Predicts Better Outcomes in Living-Donor Kidney Transplantation. Front Immunol 2019;10:2912. [PMID: 31921171 DOI: 10.3389/fimmu.2019.02912] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 Malik S, Hamer R, Shabir S, Youssouf S, Morsy M, Rashid R, Waqar S, Ghouri N. Effects of fasting on solid organ transplant recipients during Ramadan - a practical guide for healthcare professionals. Clin Med (Lond) 2021;21:e492-8. [PMID: 34507933 DOI: 10.7861/clinmed.2021-0250] [Reference Citation Analysis]
4 Ko H, Kim HK, Chung C, Han A, Min SK, Ha J, Min S. Association between medication adherence and intrapatient variability in tacrolimus concentration among stable kidney transplant recipients. Sci Rep 2021;11:5397. [PMID: 33686160 DOI: 10.1038/s41598-021-84868-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Contreras-Castillo S, Plaza A, Stojanova J, Navarro G, Carmona R, Corvalán F, Cerpa L, Sandoval C, Muñoz D, Leiva M, Castañeda LE, Farias N, Alvarez C, Llull G, Mezzano S, Ardiles L, Varela N, Rodríguez MS, Flores C, Cayún JP, Krall P, Quiñones LA. Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients. Front Pharmacol 2021;12:674117. [PMID: 34938174 DOI: 10.3389/fphar.2021.674117] [Reference Citation Analysis]
6 Park Y, Lee H, Eum SH, Kim HD, Ko EJ, Yang CW, Chung BH. Intrapatient Variability in Tacrolimus Trough Levels Over 2 Years Affects Long-Term Allograft Outcomes of Kidney Transplantation. Front Immunol 2021;12:746013. [PMID: 34659243 DOI: 10.3389/fimmu.2021.746013] [Reference Citation Analysis]
7 Schwartz JJ, Wilson S, Shi F, Elsouda D, Undre N, Kumar MSA. Prolonged-Release vs Immediate-Release Tacrolimus Capsules in Black vs White Kidney Transplant Patients: A Post Hoc Analysis of Phase III Data. Transplant Proc 2018;50:3283-95. [PMID: 30577198 DOI: 10.1016/j.transproceed.2018.08.050] [Reference Citation Analysis]
8 Ho B, Bhagat H, Schwartz JJ, Atiemo K, Daud A, Kang R, Montag SE, Zhao L, Lee E, Skaro AI, Ladner DP. Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization. Adv Ther 2019;36:1465-79. [PMID: 30941724 DOI: 10.1007/s12325-019-00904-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 McGillicuddy JW, Chandler JL, Sox LR, Taber DJ. Exploratory Analysis of the Impact of an mHealth Medication Adherence Intervention on Tacrolimus Trough Concentration Variability: Post Hoc Results of a Randomized Controlled Trial. Ann Pharmacother 2020;54:1185-93. [PMID: 32506922 DOI: 10.1177/1060028020931806] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Leino AD, Pai MP. Maintenance Immunosuppression in Solid Organ Transplantation: Integrating Novel Pharmacodynamic Biomarkers to Inform Calcineurin Inhibitor Dose Selection. Clin Pharmacokinet 2020;59:1317-34. [PMID: 32720300 DOI: 10.1007/s40262-020-00923-w] [Reference Citation Analysis]
11 Yin S, Huang Z, Wang Z, Fan Y, Wang X, Song T, Lin T. Early Monitoring and Subsequent Gain of Tacrolimus Time-In-Therapeutic Range May Improve Clinical Outcomes After Living Kidney Transplantation. Ther Drug Monit 2021;43:728-35. [PMID: 34780391 DOI: 10.1097/FTD.0000000000000881] [Reference Citation Analysis]
12 Arnau A, Benito-Hernández A, Ramos-Barrón MA, García-Unzueta MT, Gómez-Román JJ, Gómez-Ortega JM, López-Hoyos M, San Segundo D, Ruiz JC, Rodrigo E. Urinary C-X-C Motif Chemokine 10 Is Related to Acute Graft Lesions Secondary to T Cell- and Antibody-Mediated Damage. Ann Transplant 2021;26:e929491. [PMID: 33686050 DOI: 10.12659/AOT.929491] [Reference Citation Analysis]
13 Fellström B, Holmdahl J, Sundvall N, Cockburn E, Kilany S, Wennberg L. Adherence of Renal Transplant Recipients to Once-daily, Prolonged-Release and Twice-daily, Immediate-release Tacrolimus-based Regimens in a Real-life Setting in Sweden. Transplant Proc 2020;52:3238-45. [PMID: 33218668 DOI: 10.1016/j.transproceed.2020.06.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Kitamura M, Mochizuki Y, Kitamura S, Mukae Y, Nakanishi H, Ota Y, Muta K, Yamashita H, Obata Y, Iwata T, Nishikido M, Kawanami S, Takashima M, Sasaki H, Sakai H, Mukae H, Nishino T. Prediction of Nonadherence and Renal Prognosis by Pre-Transplantation Serum Phosphate Levels. Ann Transplant 2019;24:260-7. [PMID: 31073118 DOI: 10.12659/AOT.914909] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
15 Wiebe C, Rush DN, Gibson IW, Pochinco D, Birk PE, Goldberg A, Blydt-Hansen T, Karpinski M, Shaw J, Ho J, Nickerson PW. Evidence for the alloimmune basis and prognostic significance of Borderline T cell-mediated rejection. Am J Transplant 2020;20:2499-508. [PMID: 32185878 DOI: 10.1111/ajt.15860] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
16 Bunthof KLW, Al-Hassany L, Nakshbandi G, Hesselink DA, van Schaik RHN, Ten Dam MAGJ, Baas MC, Hilbrands LB, van Gelder T. A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients. Clin Transl Sci 2021. [PMID: 34905302 DOI: 10.1111/cts.13206] [Reference Citation Analysis]
17 Rahamimov R, Tifti-Orbach H, Zingerman B, Green H, Schneider S, Chagnac A, Mor E, Fox BD, Rozen-Zvi B. Reduction of exposure to tacrolimus trough level variability is associated with better graft survival after kidney transplantation. Eur J Clin Pharmacol 2019;75:951-8. [PMID: 30762079 DOI: 10.1007/s00228-019-02643-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
18 Herblum J, Dacouris N, Huang M, Zaltzman J, Prasad GVR, Nash M, Chen L. Retrospective Analysis of Tacrolimus Intrapatient Variability as a Measure of Medication Adherence. Can J Kidney Health Dis 2021;8:20543581211021742. [PMID: 34188946 DOI: 10.1177/20543581211021742] [Reference Citation Analysis]
19 Chambord J, Couzi L, Merville P, Moreau K, Xuereb F, Djabarouti S. Benefit of a pharmacist-led intervention for medication management of renal transplant patients: a controlled before-and-after study. Ther Adv Chronic Dis 2021;12:20406223211005275. [PMID: 33868624 DOI: 10.1177/20406223211005275] [Reference Citation Analysis]
20 Weber S, Dienemann T, Jacobi J, Eckardt KU, Weidemann A. Delayed graft function is associated with an increased rate of renal allograft rejection: A retrospective single center analysis. PLoS One 2018;13:e0199445. [PMID: 29928026 DOI: 10.1371/journal.pone.0199445] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
21 Tremblay S, Alloway RR. Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations. AAPS J 2017;19:1332-47. [PMID: 28717926 DOI: 10.1208/s12248-017-0119-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
22 Seibert SR, Schladt DP, Wu B, Guan W, Dorr C, Remmel RP, Matas AJ, Mannon RB, Israni AK, Oetting WS, Jacobson PA. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients. Clin Transplant 2018;32:e13424. [PMID: 30318646 DOI: 10.1111/ctr.13424] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
23 Jung HY, Lee S, Jeon Y, Choi JY, Cho JH, Park SH, Kim YL, Kim HK, Huh S, Won DI, Kim CD. Mycophenolic Acid Trough Concentration and Dose Are Associated with Hematologic Abnormalities but Not Rejection in Kidney Transplant Recipients. J Korean Med Sci 2020;35:e185. [PMID: 32567256 DOI: 10.3346/jkms.2020.35.e185] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 van Gelder T, Meziyerh S, Swen JJ, de Vries APJ, Moes DJAR. The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients. Front Pharmacol 2020;11:1142. [PMID: 32848756 DOI: 10.3389/fphar.2020.01142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
25 Jung HY, Kim SH, Seo MY, Cho SY, Yang Y, Choi JY, Cho JH, Park SH, Kim YL, Kim HK, Huh S, Won DI, Kim CD. Characteristics and Clinical Significance of De Novo Donor-Specific Anti-HLA Antibodies after Kidney Transplantation. J Korean Med Sci 2018;33:e217. [PMID: 30127706 DOI: 10.3346/jkms.2018.33.e217] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Chamoun B, Torres IB, Gabaldón A, Sellarés J, Perelló M, Castellá E, Guri X, Salcedo M, Toapanta NG, Cidraque I, Moreso F, Seron D. Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies: The Influence of TAC Exposure and Metabolism. J Clin Med 2021;10:E141. [PMID: 33406589 DOI: 10.3390/jcm10010141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Stefanović NZ, Veličković-Radovanović RM, Danković KS, Mitić BP, Paunović GJ, Cvetković MB, Cvetković TP. Combined Effect of Inter- and Intrapatient Variability in Tacrolimus Exposure on Graft Impairment Within a 3-Year Period Following Kidney Transplantation: A Single-Center Experience. Eur J Drug Metab Pharmacokinet 2020;45:749-60. [PMID: 32886348 DOI: 10.1007/s13318-020-00644-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Davis S, Gralla J, Klem P, Tong S, Wedermyer G, Freed B, Wiseman A, Cooper JE. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant 2018;18:907-15. [PMID: 28925597 DOI: 10.1111/ajt.14504] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 11.4] [Reference Citation Analysis]
29 Sablik KA, Clahsen-van Groningen MC, Hesselink DA, van Gelder T, Betjes MGH. Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. PLoS One 2018;13:e0196552. [PMID: 29746495 DOI: 10.1371/journal.pone.0196552] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
30 Heemann U, Viklicky O. Is trough level variability the new tool for identifying patients at risk for rejection after transplantation? Nephrol Dial Transplant 2017;32:214-5. [PMID: 28186537 DOI: 10.1093/ndt/gfw447] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
31 Jung HY, Cho SY, Choi JY, Cho JH, Park SH, Kim YL, Kim HK, Huh S, Won DI, Kim CD. Comparison of Transplant Outcomes for Low-level and Standard-level Tacrolimus at Different Time Points after Kidney Transplantation. J Korean Med Sci 2019;34:e103. [PMID: 30940998 DOI: 10.3346/jkms.2019.34.e103] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
32 Engen RM, Park GE, Schumacher CS, Gimferrer I, Warner P, Finn LS, Weiss NS, Smith JM. Donor-specific Antibody Surveillance and Graft Outcomes in Pediatric Kidney Transplant Recipients. Transplantation. 2018;102:2072-2079. [PMID: 29863579 DOI: 10.1097/tp.0000000000002310] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
33 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
34 Kim YH, Chiang YJ, Kim SJ, Kim MS, Park SB, Wu ST, Horita K, Nakashima Y, Jiang H, Han DJ. Safety and Efficacy of Reduced Prolonged-release Tacrolimus Exposure in De Novo Kidney Transplantation: A Randomized, Open-label, Pilot Study in Asia-OPTIMIZE Study. Transplant Direct 2019;5:e340. [PMID: 30993185 DOI: 10.1097/TXD.0000000000000877] [Reference Citation Analysis]
35 Tremblay S, Nigro V, Woodle ES, Alloway RR. Reply to "Fluctuation Does Not Mean Variability: A Pharmacokinetic Point of View". Am J Transplant 2017;17:1693. [PMID: 28248455 DOI: 10.1111/ajt.14248] [Reference Citation Analysis]
36 Unagami K, Ishida H, Furusawa M, Kitajima K, Hirai T, Kakuta Y, Toki D, Shimizu T, Omoto K, Okumi M, Nitta K, Tanabe K. Influence of a low-dose tacrolimus protocol on the appearance of de novo donor-specific antibodies during 7 years of follow-up after renal transplantation. Nephrol Dial Transplant 2021;36:1120-9. [PMID: 33280052 DOI: 10.1093/ndt/gfaa258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Cochrane AB, Veasey TM. Is tacrolimus by any generic name as sweet? J Heart Lung Transplant 2021;40:573-4. [PMID: 34030973 DOI: 10.1016/j.healun.2021.04.006] [Reference Citation Analysis]
38 Alghanem SS, Soliman MM, Alibrahim AA, Gheith O, Kenawy AS, Awad A. Monitoring Tacrolimus Trough Concentrations During the First Year After Kidney Transplantation: A National Retrospective Cohort Study. Front Pharmacol 2020;11:566638. [PMID: 33658922 DOI: 10.3389/fphar.2020.566638] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Campbell KR, Martins R, Davis S, Juarez-Colunga E. Dynamic prediction based on variability of a longitudinal biomarker. BMC Med Res Methodol 2021;21:104. [PMID: 33992081 DOI: 10.1186/s12874-021-01294-x] [Reference Citation Analysis]
40 Jung HY, Jeon Y, Seong SJ, Seo JJ, Choi JY, Cho JH, Park SH, Kim CD, Yoon YR, Yoon SH, Lee JS, Kim YL. ICT-based adherence monitoring in kidney transplant recipients: a randomized controlled trial. BMC Med Inform Decis Mak 2020;20:105. [PMID: 32522263 DOI: 10.1186/s12911-020-01146-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 January SE, Hagopian JC, Nesselhauf NM, Progar K, Horwedel TA, Santos RD. Clinical Experience with Extended-Release Tacrolimus in Older Adult Kidney Transplant Recipients: A Retrospective Cohort Study. Drugs Aging 2021;38:397-406. [PMID: 33755934 DOI: 10.1007/s40266-021-00842-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Thongprayoon C, Hansrivijit P, Kovvuru K, Kanduri SR, Bathini T, Pivovarova A, Smith JR, Cheungpasitporn W. Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients. J Clin Med 2020;9:E2193. [PMID: 32664531 DOI: 10.3390/jcm9072193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
43 Gäckler A, Dolff S, Rohn H, Korth J, Wilde B, Eisenberger U, Mitchell A, Kribben A, Witzke O. Randomized, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants. BMC Nephrol 2019;20:167. [PMID: 31088392 DOI: 10.1186/s12882-019-1340-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
44 Heeney S, Szempruch KR, Lee RM, Mintz A, Serrano P, Detwiler R, Doligalski C. The Effect of Tacrolimus Trough Variability on Kidney Transplant Outcomes. Transplant Proc 2020;52:3129-33. [PMID: 32896383 DOI: 10.1016/j.transproceed.2020.07.016] [Reference Citation Analysis]
45 Serper M, Ladner DP, Curtis LM, Nair SS, Hur SI, Kwasny MJ, Ho B, Friedewald J, Reese PP, Abecassis MMI, Wolf MS. Transplant regimen adherence for kidney recipients by engaging information technologies (TAKE IT): Rationale and methods for a randomized controlled trial of a strategy to promote medication adherence among transplant recipients. Contemp Clin Trials 2021;103:106294. [PMID: 33515781 DOI: 10.1016/j.cct.2021.106294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Dreyer GJ, de Fijter JW. Transplanting the Elderly: Mandatory Age- and Minimal Histocompatibility Matching. Front Immunol 2020;11:359. [PMID: 32226428 DOI: 10.3389/fimmu.2020.00359] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
47 Kim J, Wilson S, Undre NA, Shi F, Kristy RM, Schwartz JJ. A Novel, Dose-Adjusted Tacrolimus Trough-Concentration Model for Predicting and Estimating Variance After Kidney Transplantation. Drugs R D 2019;19:201-12. [PMID: 31073875 DOI: 10.1007/s40268-019-0271-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
48 Uchida J, Iwai T, Nakatani T. Introduction of everolimus in kidney transplant recipients at a late posttransplant stage. World J Transplantation 2018; 8(5): 150-155 [PMID: 30211023 DOI: 10.5500/wjt.v8.i5.150] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
49 Duncan S, Annunziato RA, Dunphy C, LaPointe Rudow D, Shneider BL, Shemesh E. A systematic review of immunosuppressant adherence interventions in transplant recipients: Decoding the streetlight effect. Pediatr Transplant 2018;22. [PMID: 29218760 DOI: 10.1111/petr.13086] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
50 Lieb M, Hepp T, Schiffer M, Opgenoorth M, Erim Y. Accuracy and concordance of measurement methods to assess non-adherence after renal transplantation - a prospective study. BMC Nephrol 2020;21:114. [PMID: 32234021 DOI: 10.1186/s12882-020-01781-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
51 Larpparisuth N, Pongnatcha T, Panprom P, Promraj R, Premasathian N, Vongwiwatana A. High Intrapatient Variability in Tacrolimus Exposure Calculated Over a Long Period Is Associated With De Novo Donor-Specific Antibody Development and/or Late Rejection in Thai Kidney Transplant Patients Receiving Concomitant CYP3A4/5 Inhibitors. Ther Drug Monit 2021;43:624-9. [PMID: 33278239 DOI: 10.1097/FTD.0000000000000850] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Li Y, Yan L, Li Y, Wan Z, Bai Y, Wang X, Hu S, Wu X, Yang C, Fan J, Xu H, Wang L, Shi Y. Development and validation of routine clinical laboratory data derived marker-based nomograms for the prediction of 5-year graft survival in kidney transplant recipients. Aging (Albany NY) 2021;13:9927-47. [PMID: 33795527 DOI: 10.18632/aging.202748] [Reference Citation Analysis]
53 Stefanović N, Veličković-Radovanović R, Danković K, Pavlović I, Catić-Đorđević A, Bašić J, Despotović M, Jevtović-Stoimenov T, Mitić B, Cvetković T. Effect of the Interrelation between CYP3A5 Genotype, Concentration/Dose Ratio and Intrapatient Variability of Tacrolimus on Kidney Graft Function: Monte Carlo Simulation Approach. Pharmaceutics 2021;13:1970. [PMID: 34834385 DOI: 10.3390/pharmaceutics13111970] [Reference Citation Analysis]
54 Shen CL, Wu BS, Lien TJ, Yang AH, Yang CY. BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection. Viruses 2021;13:487. [PMID: 33809472 DOI: 10.3390/v13030487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Del Bello A, Gaible C, Longlune N, Hebral AL, Esposito L, Gandia P, Kamar N. Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation. Front Pharmacol 2021;12:602764. [PMID: 34690747 DOI: 10.3389/fphar.2021.602764] [Reference Citation Analysis]
56 Sharma A, Cherukuri A, Mehta RB, Sood P, Hariharan S. High Calcineurin Inhibitor Intrapatient Variability Is Associated With Renal Allograft Inflammation, Chronicity, and Graft Loss. Transplant Direct 2019;5:e424. [PMID: 30882028 DOI: 10.1097/TXD.0000000000000862] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
57 Prezelin-Reydit M, Dubois V, Caillard S, Parissiadis A, Etienne I, Hau F, Albano L, Pourtein M, Barrou B, Taupin JL, Mariat C, Absi L, Vigneau C, Renac V, Guidicelli G, Visentin J, Merville P, Thaunat O, Couzi L. Prospective Measures of Adherence by Questionnaire, Low Immunosuppression and Graft Outcome in Kidney Transplantation. J Clin Med 2021;10:2032. [PMID: 34068497 DOI: 10.3390/jcm10092032] [Reference Citation Analysis]
58 Kim EJ, Kim SJ, Huh KH, Kim BS, Kim MS, Kim SI, Kim YS, Lee J. Clinical significance of tacrolimus intra-patient variability on kidney transplant outcomes according to pre-transplant immunological risk. Sci Rep 2021;11:12114. [PMID: 34108576 DOI: 10.1038/s41598-021-91630-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Peters FS, Peeters AMA, Hofland LJ, Betjes MGH, Boer K, Baan CC. Interferon-Gamma DNA Methylation Is Affected by Mycophenolic Acid but Not by Tacrolimus after T-Cell Activation. Front Immunol 2017;8:822. [PMID: 28747916 DOI: 10.3389/fimmu.2017.00822] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
60 Abedini S, Gøransson L, Cockburn E, Kilany S, Holdaas H. Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study. Transplant Direct 2018;4:e338. [PMID: 29464199 DOI: 10.1097/TXD.0000000000000755] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
61 Mo H, Kim SY, Min S, Han A, Ahn S, Min SK, Lee H, Ahn C, Kim Y, Ha J. Association of Intrapatient Variability of Tacrolimus Concentration With Early Deterioration of Chronic Histologic Lesions in Kidney Transplantation. Transplant Direct 2019;5:e455. [PMID: 31321291 DOI: 10.1097/TXD.0000000000000899] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
62 González-vílchez F, Crespo-leiro MG, Delgado-jiménez J, Pérez-villa F, Segovia-cubero J, Díaz-molina B, Mirabet-pérez S, Arizón del Prado JM, Blasco-peiró T, Martínez-sellés M, Almenar-bonet L, Garrido-bravo I, Rábago G, Vázquez de Prada JA. Impacto de la variabilidad intrapaciente en la concentración sanguínea de anticalcineurínicos en los resultados del trasplante cardiaco. Revista Española de Cardiología 2022;75:129-40. [DOI: 10.1016/j.recesp.2021.02.004] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Kuypers DRJ. Tacrolimus Formulations and African American Kidney Transplant Recipients: When Do Details Matter? Am J Kidney Dis 2018;71:302-5. [PMID: 29477174 DOI: 10.1053/j.ajkd.2017.10.020] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]